Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study

Drug Design, Development and Therapy
Patrick T UdvardiAndrea G Ludolph

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is the most frequently diagnosed neurodevelopmental disorder. The norepinephrine transporter (NET) inhibitor atomoxetine, the first nonstimulant drug licensed for ADHD treatment, also acts as an N-methyl-D-aspartate receptor (NMDAR) antagonist. The compound's effects on gene expression and protein levels of NET and NMDAR subunits (1, 2A, and 2B) are unknown. Therefore, adolescent Sprague Dawley rats were treated with atomoxetine (3 mg/kg, intraperitoneal injection [i.p.]) or saline (0.9%, i.p.) for 21 consecutive days on postnatal days (PND) 21-41. In humans, atomoxetine's earliest clinical therapeutic effects emerge after 2-3 weeks. Material from prefrontal cortex, striatum (STR), mesencephalon (MES), and hippocampus (HC) was analyzed either directly after treatment (PND 42) or 2 months after termination of treatment (PND 101) to assess the compound's long-term effects. In rat brains analyzed immediately after treatment, protein analysis exhibited decreased levels of the NET in HC, and NMDAR subunit 2B in both STR and HC; the transcript levels were unaltered. In rat brains probed 2 months after final atomoxetine exposure, messenger RNA analysis also revealed significantly reduced...Continue Reading

References

Dec 1, 1973·Analytical Biochemistry·W Schaffner, C Weissmann
May 1, 1994·The Journal of Comparative Neurology·D G StandaertJ B Penney
Jun 12, 2001·Current Opinion in Neurobiology·S Cull-CandyM Farrant
Jul 13, 2001·Biochemical Pharmacology·C IkonomidouJ W Olney
Jun 8, 2002·Annual Review of Neuroscience·Roberto Malinow, Robert C Malenka
Jul 11, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Christopher J KratochvilDavid Michelson
Aug 27, 2002·Nature Neuroscience·Bo LiLynn A Raymond
Nov 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Frank P BymasterKenneth W Perry
Jan 28, 2003·Biological Psychiatry·Frank P MacMasterVivek Kusumakar
Aug 5, 2003·Clinical Neuropharmacology·Normand CarreyMathias Schmidt
Oct 15, 2003·Neuron·David S Bredt, Roger A Nicoll
Jun 15, 2004·Current Opinion in Neurobiology·Charles F Stevens
Jun 26, 2004·Annual Review of Neuroscience·Thomas C Sudhof
Jul 19, 2005·Lancet·Joseph Biederman, Stephen V Faraone
Jun 1, 2006·The Annals of Pharmacotherapy·Aaron P GibsonM Lynn Crismon
Jul 25, 2006·Cell and Tissue Research·Georg Köhr
Nov 8, 2006·Current Opinion in Pharmacology·Pierre Paoletti, Jacques Neyton
Mar 9, 2007·Journal of Child and Adolescent Psychopharmacology·Normand J CarreyMatthias H Schmidt
Jun 2, 2007·The American Journal of Psychiatry·Guilherme PolanczykLuis Augusto Rohde
Jun 9, 2007·Journal of Pediatric Psychology·Thomas J SpencerEric Mick
Jun 23, 2007·Neurochemistry International·Salomon Z Langer
Dec 1, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Robert L FindlingJoseph R Calabrese
Oct 17, 2008·Nature·Melissa B Ramocki, Huda Y Zoghbi
Oct 22, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·William KielbasaRobert Stratford

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Assay
electrophoresis

Software Mentioned

geNorm
SPSS
ImageJ

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.